Compare Cytokinetics Inc (CYTK) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Valero Energy Corporation — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Valero Energy Corporation trades at $439.78 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 14.8× Cytokinetics Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Valero Energy Corporation for 56 Days on average.
| CYTK | VLO | |
|---|---|---|
Market Cap | $8.62B | $127.78B |
Volume | 2,594,626 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $87.26 | $443.80 |
52-Week Low | $54.76 | $156.39 |
Typical Hold Time | 19 Days | 56 Days |
Enterprise Value | $8.72B | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Valero Energy (VLO) trades at $424.10, up 1.16% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue has declined from $176.4B in 2022 to $122.7B in 2025. Analyst consensus remains positive with 57% buy ratings, though the current price exceeds the $408.10 consensus target. Recent news highlights refining sector strength and institutional buying interest.
VLO presents a mixed outlook with strong operational performance offset by revenue pressures. The stock's premium valuation (P/E 17.69) and overbought RSI suggest near-term caution, but projected 2026 earnings growth ($7.2B net income) and dividend yield provide support. Key risks include refining margin volatility and potential policy impacts from diesel export restrictions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
